A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Aclidinium (Tudorza Pressair)

First FDA approval2015-07-01
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$7.1M in CY2024 Part D spend11K claims · 3K beneficiaries · 329 plans surveyed

Lowest NADAC
$258.47/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$344.00
Across all dosage forms in distribution.
Highest NADAC
$429.53
Range is tight.
Plans with PA
2 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Aclidinium used for?

Aclidinium is a this drug class medication tracked in Medicare Part D.

Is there a generic for Aclidinium?

No. Aclidinium is brand-only with no generic equivalents currently in market.

How much does my plan pay for Aclidinium?

Across 329 Part D plans, Aclidinium averages $344.00/unit (NADAC). Lowest available: $258.47/unit. Highest in distribution: $429.53/unit.

Is Aclidinium on the FDA shortage list?

No. Aclidinium is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (1 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.